IMUX – immunic, inc. (US:NASDAQ)
Stock Stats
News
Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Immunic (NASDAQ:IMUX) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.
Immunic (NASDAQ:IMUX) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis [Yahoo! Finance]
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Aberdeen Group plc
Form 8-K IMMUNIC, INC. For: Jan 05
Form 8-K IMMUNIC, INC. For: Dec 29
Form SCHEDULE 13G IMMUNIC, INC. Filed by: JANUS HENDERSON GROUP PLC
Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Alyeska Investment Group, L.P.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.